Abstract
The activity and regulation of a number of mitogenic signaling pathways is aberrant in astrocytomas, and this is thought to play a crucial role in the development of these tumors. The cascade of events leading to the formation and the progression from low-grade to high-grade astrocytomas is well characterized. These events include activating mutations, amplification, and overexpression of various growth factor receptors (e.g. epidermal growth factor receptor (EGFR), platelet derived growth factor receptor (PDGFR), c-Met), signaling intermediates (e.g. Ras and Protein kinase C (PKC)), and cell cycle regulatory molecules (e.g. mouse double minute-2 (Mdm2), cyclin-dependent kinase-4 (CDK4), and CDK6), that positively regulate proliferation and cell cycle progression. Inactivating mutations and deletions of signaling and cell cycle regulatory molecules that negatively regulate proliferation and cell cycle progression (e.g. p53, p16/INK4a, p14/ARF, p15/INK4b, retinoblastoma protein (Rb), and Phosphatase and tensin homologue deleted from chromosome 10 (PTEN)) also participate actively in the development of the transformed phenotype. Several mitogenic pathways are also stimulated via an autocrine loop, with astrocytoma cells expressing both the receptors and the respective cognate ligand. Due to the multitude of factors involved in astrocytoma pathogenesis, attempts to target a single pathway have not given satisfactory results. The simultaneous targeting of several pathways or the targeting of signaling intermediates, such as Ras or PKC, situated downstream of many growth factor receptor signaling pathways may show more efficacy in astrocytoma therapy. We will give an overview of how the combination of these aberrations drive astrocytoma cells into a relentless proliferation and how these signaling molecules may constitute relevant therapeutic targets.
Similar content being viewed by others
References
Kleihues P, Soylemezoglu F, Schauble B, Scheithauer BW, Burger PC: Histopathology, classification, and grading of gliomas. Glia 15: 211–221, 1995
Von Deimling A, Louis DN, Wiestler OD: Molecular pathways in the formation of gliomas. Glia 15: 328–338, 1995
Lang FF, Miller DC, Koslow M, Newcomb EW: Pathways leading to glioblastoma multiforme: a molecular analysis of genetic alterations in 65 astrocytic tumors. J Neurosurg 81: 427–436, 1994
Biernat W, Tohma Y, Yonekawa Y, Kleihues P, Ohgaki H: Alterations of cell cycle regulatory genes in primary (de novo) and secondary glioblastomas. Acta Neuropathol 94: 303–309, 1997
Dirks PB, Rutka JT: Current concepts in neuro-oncology: The cell cycle, a review. Neurosurgery 40: 1000–1015, 1997
Sherr CJ: Tumor surveillance via the ARF-p53 pathway. Genes Dev 12: 2984–2991, 1998
Weinberg RA: The retinoblastoma protein and cell cycle control. Cell 81: 323–330, 1995
Ichimura K, Bondesson Bolin M, Goike HM, Schmidt EE, Moshref A, Collins VP: Deregulation of the p14-ARF/ MDM2/p53 pathway is a prerequisite for human astrocytic gliomas with G1/S transition control gene abnormalities. Cancer Res 60: 417–424, 2000
Collins VP: Gene amplification in human gliomas. Glia 15: 289–296, 1995
Reifenberger G, Liu L, Ichimura K, Schmidt EE, Collins VP: Amplification and overexpression of the Mdm2 gene in a subset of human malignant gliomas without p53 mutations. Cancer Res 53: 2736–2739, 1993
Schmidt EE, Ichimura K, Reifenberger G, Collins VP: CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas. Cancer Res 54: 6321–6324, 1994
He J, Olson JJ, James CD: Lack of p16INK4 or retinoblastoma protein (pRb), or amplification-associated overexpression of CDK4 is observed in distinct subsets of malignant glial tumors ad cell lines. Cancer Res 55: 4833–4836, 1995
Ichimura K, Schmidt EE, Goike HM, Collins VP: Human glioblastomas with no alterations of the CDK2A (p16/INK4A/MTS1) and CDK4 genes have frequent mutations of the retinoblastoma gene. Oncogene 13: 1065–1072, 1996
Burns KL, Ueki K, Jhung SL, Koh J, Louis DN: Molecular genetics correlates of p16, CDK4, and pRb immunochemistry in glioblastomas. J Neuropathol Exp Neurol 57: 122–130, 1998
Hackel PO, Zwick E, Prenzel N, Ullrich A: Epidermal growth factor receptors: critical mediators of multiple receptor pathways. Curr Op Cell Biol 11: 184–189, 1999
Libermann TA, Razon N, Bantal AD, Yarden Y, Schlessinger J, Soreq H: Expression of epidermal growth factor receptors in human brain tumors. Cancer Res 44: 753–760, 1984
Bigner SH, Burger PC, Wong AJ, Werner MH, Hamilton SR, Muhlbaier LH, Vogelstein B, Bigner DD: Gene amplification in malignant human gliomas: Clinical and histopathological aspects. J Neuropathol Exp Neurol 47: 191–205, 1988
Worm K, Dabbagh P, Schwechhmeimer K: Reverse transcriptase polymerase chain reaction as a reliable method to detect epidermal growth factor receptor exon 2–7 gene deletion in human glioblastomas. Hum Pathol 30: 222–227, 1999
Ekstrand AJ, James CD, Cavenee WK, Seliger B, Pettersson RF, Collins VP: Genes for epidermal growth factor receptor, transforming growth factor alpha, and epidermal growth factor and their expression in human gliomas in vivo. Cancer Res 51: 2164–2172, 1991
Wong AJ, Ruppert JM, Bigner SH, Grzeschik CH, Humphrey PA, Bigner DD, Vogelstein B: structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc Natl Acad Sci USA 89: 2965–2969, 1992
Wikstrand CJ, Hale LP, Batra SK, Hill ML, Humphrey PA, Kurpad SN, McLendon RE, Moscatello D, Pegram CN, Reist CJ, Traweek ST, Wong AJ, Zalutski MR, Bigner DD: Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. Cancer Res 55: 3140–3148, 1995
Huang HJS, Nagane M, Klingbeil CK, Lin H, Nishikawa R, Ji XD, Huang CM, Gill GN, Wiley HS, Cavenee WK: The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling. J Biol Chem 272: 2927–2935, 1997
Ekstrand AJ, Longo N, Hamid ML, Olson JJ, Liu L, Collins VP, James CD: Functional characterization of an EGF receptor with a truncated extracellular domain expressed in glioblastomas with EGFR gene amplification. Oncogene 9: 2313–2320, 1994
Ekstrand AJ, Liu L, He L, Hamid ML, Longo N, Collins VP, James CD: Altered subcellular location of an activated and tumour associated epidermal growth factor receptor. Oncogene 10: 1455–1460, 1995
Nishikawa R, Ji XD, Harmon RC, Lazar CS, Gill GN, Cavenee WK, Huang HJS: Amutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc Natl Acad Sci USA 91: 7727–7731, 1994
Nagane M, Coufal F, Lin H, Bogler O, Cavenee WK, Huang HJS: A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis. Cancer Res 56: 5079–5086, 1996
Sugawa N, Yamamoto K, Ueda S, Morita N, Kita M, Nishino H, Fushiki S, Okabe T: Function of aberrant EGFR in malignant gliomas. Brain Tumor Pathol 15: 53–57, 1998
Nagane M, Levitzski A, Gazit A, Cavenee WK, Huang HJS: Drug resistance of human glioblastoma cells conferred by a tumor specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3-like proteases. Proc Natl Acad Sci USA 95: 5724–5729, 1998
Prigent SA, Nagane M, Lin H, Huvar I, Boss GR, Feramisco JR, Cavenee WK, Huang HJS: Enhanced tumorigenic behavior of glioblastoma cells expressing a truncated epidermal growth factor receptor is mediated through the Ras-Shc-Grb2 pathway. J Biol Chem 271: 25639–25645, 1996
Montgomery RB, Moscatello DK, Wong AJ, Cooper JA, Stahl WL: Differential modulation of mitogen-activated protein (MAP) kinase/extracellular signal regulated kinase and MAP kinase activities by a mutant epidermal growth factor receptor. J Biol Chem 270: 30562–30566, 1995
Holland EC, Hively WP, DePinho RA, Varmus HE: A constitutively active epidermal growth factor receptor cooperates with disruption of G1 cell cycle arrest pathways to induce glioma like lesions in mice. Genes Dev 12: 3675–3685, 1998
Holland EC: A mouse model for glioma: Biology, pathology, and therapeutic opportunities. Toxicol Pathol 28: 171–177, 2000
Tang P, Steck PA, Yung WKA: The autocrine loop of TGF alpha/EGFR and brain tumors. J Neuro-Oncol 35: 303–314, 1997
Mishima K, Higashiyama S, Asai A, Yamaoka K, Nagashima Y, Taniguchi N, Kitanaka C, Kirino T, Kuchino Y: Heparin binding epidermal growth factor-like growth factor stimulates mitogenic signaling and is highly expressed in human malignant gliomas. Acta Neuropathol 96: 322–328, 1998
Maruno M, Kovach JS, Kelly PJ, Yanagihara T: Transforming growth factor-alpha, epidermal growth factor receptor, and proliferating potential in benign and malignant gliomas. J Neurosurg 75: 97–102, 1991
Nister M, Libermann TA, Betsholtz C, Pettersson M, Claesson-Welsh L, Heldin CH, Schlessinger J, Westermark B: Expression of messenger RNAs for platelet-derived growth factor and transforming growth factor-alpha and their receptors in human malignant glioma cell lines. Cancer Res 48: 3910–3918, 1988
Tang P, Jasser SA, Sung JC, Shi Y, Steck PA, Yung WK: Transforming growth factor-alpha antisense vectors can inhibit glioma cell growth. J Neuro-Oncol 43: 127–135, 1999
Hung MC, Lau YK: Basic science of HER-2/Neu: a review. Semin Oncol 26: 51–59, 1999
Stragliotto G, Vega F, Stasiecki P, Gropp P, Poisson M, Delattre JY: Multiple infusions of anti-epidermal growth factor receptor (EGFR) monoclonal antibody (EMD 55,900) in patients with recurrent malignant gliomas. Eur J Cancer 32: 636–640, 1996
Wersall P, Ohlsson I, Biberfeld P, Collins VP, Von Krusenstjerna S, Larsson S, Mellstedt H, Boethius J: Intratumoral infusion of the monoclonal antibody, mAb 425, against the epidermal-growth-factor receptor in patients with advanced malignant glioma. Cancer Immunol Immunother 44: 157–164, 1997
Tian XX, Lam PYP, Chen J, Pang JCS, To SST, Di-Tomaso E, Ng HK: Antisense epidermal growth factor receptor RNA transfection in human malignant glioma cells leads to inhibition of proliferation and induction of differentiation. Neuropathol Applied Neurobiol 24: 389–396, 1998
Yamazaki H, Kijima H, Ohnishi Y, Abe Y, Oshika Y, Tsuchida T, Tokunaka T, Tsugu A, Ueyama Y, Tamaoki N, Nakamura M: Inhibition of tumor growth by ribozymemediated suppression of aberrant epidermal growth factor receptor gene expression. J Natl Cancer Inst 90: 581–587, 1998
Halatsch ME, Schmidt U, Botefur IC, Holland JF, Ohnuma T: Marked inhibition of glioblastoma target cell tumorigenicity in vitro by retrovirus-mediated transfer of a hairpin ribozyme against deletion mutant epidermal growth factor receptor messenger RNA. J Neurosurg 92: 297–305, 2000
Rourke DMO, Qian X, Zhang HT, Davis JG, Nute E, Meinkoth J, Greene MI: Trans receptor inhibition of human glioblastoma cells by erbB family ectodomain. Proc Natl Acad Sci USA 94: 3250–3255
Han Y, Gacusana Caday C, Nanda A, Cavenee WK, Huang HJS: Tyrphostin AG 1478 preferentially inhibits human glioma cells expressing truncated rather than wild type epidermal growth factor. Cancer Res 56: 3859–3861, 1996
Westermark B, Heldin CH, Nister M: Platelet-derived growth factor in human glioma. Glia 15: 257–263, 1995
Nister M, Claesson-Welsh L, Eriksson A, Heldin CH, Westermark B: Differential expression of platelet-derived growth factor receptors in human malignant cell lines. J Biol Chem 266: 16755–16763, 1991
Hermanson M, Funa K, Hartman M, Claesson-Welsh L, Heldin CH, Westermark B, Nister M: Platelet-derived growth factor (PDGF) and its receptors in human glioma tissue: expression of mRNA and protein suggests the presence of autocrine and paracrine loops. Cancer Res 52: 3213–3219, 1992
Fleming TP, Saxena A, Clark WC, Robertson JT, Oldfield EH, Aaronson SA, Ali IU: Amplification and/or overexpression of platelet-derived growth factor receptors and epidermal growth factor receptor in human glial tumors. Cancer Res 52: 4550–4553, 1992
Shamah SM, Stiles CD, Guha A: Dominant negative mutants of platelet-derived growth factor revert the transformed phenotype of human astrocytoma cells. Mol Cell Biol 13: 7203–7212, 1993
Strawn L, Mann E, Elliger SS, Chu LM, Germain LL, Neiderfellner G, Ullrich A, Shawver LK: Inhibition of glioma cell growth by a truncated platelet derived growth factor β receptor. J Biol Chem 269: 21215–21222, 1994
Vassbotn FS, Ostman A, Langeland N, Holmsen H, Westermark B, Heldin CH, Nister M: Evidence for an activated PDGF pathway which contributes to the transformed phenotype of A172 glioblastoma. J Cell Physiol 158: 381–389, 1994
Uhrbom L, Hesselager G, Nister M, Westermark B: Induction of brain tumors in mice using a recombinant platelet-derived growth factor B-chain retrovirus. Cancer Res 58: 5275–5279, 1998
Shawver LK, Schwartz DP, Mann E, Chen H, Tsai J, Chu L, Taylorson L, Longhi M, Meredith S, Germain L, Jacobs JS, Tang C, Ullrich A, Berens ME, Hersh E, McMahon G, Hirth KP, Powell TJ: Inhibition of platelet-derived growth factor-mediated signal transduction and tumor growth by N-[4-(trifluoromethyl)-phenyl]5-methylisoxazole-4-carboxamide. Clin Cancer Res 3: 1167–1177, 1997
Ahn HY, Hadizadeh KR, Seul C, Yun YP, Vetter H, Sachinidis A: Epigallocathechin-3 Gallate Selectively Inhibits the PDGF-BB-induced Intracellular Signaling Transduction Pathway in Vascular Smooth Muscle Cells and Inhibits Transformation of sis-transfected NIH 3T3 Fibroblasts and Human Glioblastoma Cells (A172). Mol Biol Cell 10: 1093–1104, 1999
Klint P, Claesson-Welsh L: Signal transduction by fibroblast growth factor receptors. Front Biosci 4: 165–177, 1999
Morrison RS, Yamaguchi F, Bruner JM, Tang M, McKeehan W, Berger MS: Fibroblast growth factor receptor gene expression and immunoreactivity are elevated in human glioblastoma multiforme. Cancer Res 54: 2794–2799, 1994
Ueba T, Takahashi JA, Fukumoto M, Ohta M, Ito N, Oda Y, Kikuchi H, Hatanaka M: Expression of fibroblast growth factor receptor-1 in human glioma and meningioma tissues. Neurosurgery 34: 221–225, 1994
Yamaguchi F, Saya H, Bruner JM, Morrison RS: Differential expression of two fibroblast growth factor-receptor genes is associated with malignant progression in human astrocytomas. Proc Natl Acad Sci USA 91: 484–488, 1994
Morrison RS, Yamaguchi F, Saya H, Bruner JM, Yahanda AM, Donehower LA, Berger M: Basic fibroblast growth factor and fibroblast growth factor receptor I are implicated in the growth of human astrocytomas. J Neuro Oncol 18: 207–216, 1994
Bredel M, Pollack IF, Campbell JW, Hamilton RL: Basic fibroblast growth factor expression as a predictor of prognosis in pediatric high-grade gliomas. Clin Cancer Res 3: 157–164, 1997
Yamada SM, Yamaguchi F, Brown R, Berger MS, Morrison RS: Suppression of glioblastoma cell growth following antisense oligonucleotide-mediated inhibition of fibroblast growth factor receptor expression. Glia 28: 66–76, 1999
Segal DH, Germano IM, Bederson JB: Effects of basic fibroblast growth factor on in vivo cerebral tumorigenesis in rats. Neurosurgery 40: 1027–1033, 1997
Holland EC, Varmus HE: Basic fibroblast growth factor induces cell migration and proliferation after glia-specific gene transfer in mice. Proc Natl Acad Sci USA 95: 1218–1223, 1998
Ueba T, Kaspar B, Zhao X, Gage FH: Repression of human fibroblast growth factor 2 by a novel transcription factor. J Biol Chem 274: 10382–10387, 1999
Murai N, Ueba T, Takahashi JA, Yang HQ, Kikuchi H, Hiai H, Hatanaka M, Fukumoto M: Apoptosis of human glioma cells in vitro and in vivo induced by a neutralizing antibody against human basic fibroblast growth factor. J Neurosurg 85: 1072–1077, 1996
Moriyama T, Kataoka H, Hamasuna R, Yokogami K, Uehara H, Kawano H, Goya T, Tsubouchi H, Koono M, Wakisaka S: Up-regulation of vascular endothelial growth factor induced by hepatocyte growth factor stimulation in human glioma cells. Biochem Biophys Res Commun 249: 73–77, 1998
Nabeshima K, Shimao Y, Sato S, Kataoka H, Moriyama T, Kawano H, Wakisaka S, Koono M: Expression of c-Met correlates with grade of malignancy in human astrocytic tumors: an immunohistochemical study. Histopathol 31: 436–443, 1997
Moriyama T, Kataoka H, Kawano H, Yokogami K, Nakano S, Goya T, Uchino H, Koono M, Wakisaka S: Comparative analysis of expression of hepatocyte growth factor and its receptor, c-met, in gliomas, meningiomas and schwannomas in human. Cancer Lett 124: 149–155, 1998
Koochekpour S, Jeffers M, Rulong S, Taylor G, Klineberg E, Hudson EA, Resau JH, Vande Woude GF: Met and hepatocyte growth factor expression in human gliomas. Cancer Res 57: 5391–5398, 1997
Laterra J, Rosen E, Nam M, Ranganathan S, Fielding K, Johnston P: Scatter factor/hepatocyte growth factor expression enhances human glioblastoma tumorigenicity and growth. Biochem Biophys Res Commun 235: 743–747, 1997
Abounader R, Ranganathan S, Lal B, Fielding K, Book A, Dietz H, Burger P, Laterra J: Reversion of human glioblastoma malignancy by U1 small nuclear RNA/ribozyme targeting of scatter factor/hepatocyte growth factor and c-met expression. J Natl Cancer Inst 91: 1548–1556, 1999
Tada M, Diserens AC, Desbaillets I, De Tribolet N: Analysis of cytokine receptor messenger RNA expression in human glioblastoma cells and normal astrocytes by reverse-transcription polymerase chain reaction. J Neurosurg 80: 1063–1073, 1994
Kristt DA, Reedy E, Yarden Y: Receptor tyrosine kinase expression in astrocytic lesions: similar features in gliosis and glioma. Neurosurgery 33: 106–115, 1993
Berdel WE, De Vos S, Maurer J, Oberberg D, Von Marschall Z, Schroeder JK, Li J, Ludwig WD, Kreuser ED, Thiel E, Herrmann F: Recombinant human stem cell factor stimulates growth of a human glioblastoma cell line expressing c-kit protooncogene. Cancer Res 52: 3498–3502, 1992
Stanulla M, Welte K, Hadam MR, Pietsch T: Co-expression of stem cell factor and its receptor c-kit in human malignant glioma cell lines. Acta Neuropathol 89: 158–165, 1995
Giancotti FG, Ruoslahti E: Integrin signaling. Science 285: 1028–1032, 1999
Schwartz MA: Integrins, oncogenes, and anchorage independence. J Cell Biol 139: 575–578, 1997
Zhu X, Assoian RK: Integrin-dependent activation of MAP kinase: a link to shape-dependent cell proliferation. Mol Biol Cell 6: 273–282, 1995
Schlaepfer DD, Hunter T: Focal adhesion kinase overexpression enhances Ras-dependent integrin signaling to ERK2/mitogen activated protein kinase through interaction with and activation of c-Src. J Biol Chem 272: 13189–13195, 1997
Zhao JH, Reiske H, Guan JL: Regulation of the cell cycle by focal adhesion kinase. J Cell Biol 143: 1997–2000, 1998
Oktay M, Wary KK, Dans M, Birge RB, Giancotti FG: Integrin-mediated activation of focal adhesion kinase is required for signaling to Jun NH2-terminal kinase and progression through the G1 phase of the cell cycle. J Cell Biol 145: 1461–1469, 1999
Uhm JH, Gladson CL, Rao JS: The role of integrins in the malignant phenotype of gliomas. Front Biosci 4: 188–199, 1999
Besson A, Robbins SM, Yong VW: PTEN/MMAC1/TEP1 in signal transduction and tumorigenesis. Eur J Biochem 263: 605–611, 1999
Wang SI, Puc J, Li J, Bruce JN, Cairns P, Sidranski D, Parsons R: Somatic mutations of PTEN in glioblastoma multiforme. Cancer Res 57: 4183–4186, 1997
Bostrom J, Cobbers JMJL, Wolter M, Tabatabai G, Weber RG, Lichter P, Collins VP, Reifenberger G: Mutations of the PTEN/MMAC1 tumor suppressor gene in a subset of glioblastomas but not in meningiomas with loss of chromosome 10q. Cancer Res 58: 29–33, 1998
Liu W, James CD, Frederick L, Alderete BE, Jenkins RB: PTEN/MMAC1 mutations and EGFR amplification in glioblastomas. Cancer Res 57: 4997–5000, 1997
Tohma Y, Gratas C, Biernat W, Peraud A, Fukuda M, Yonekawa Y, Kleihues P, Ohgaki H: PTEN/MMAC1 mutations are frequent in primary glioblastomas (de novo) but not in secondary glioblastomas. J Neuropathol Exp Neurol 57: 684–689, 1998
Wayne I, Johnson DE, Vaillancourt MT, Avanzini J, Morimoto A, Demers GW, Wills KN, Shabram PW, Bolen JB, Tavtigian SV, Bookstein R: Suppression of tumorigenicity of glioblastoma cells by adenovirus mediated MMAC1/PTEN gene transfer. Cancer Res 58: 2331–2334, 1998
Furnari FB, Lin H, Huang HJS, Cavenee WK: Growth suppression of glioma cells by PTEN requires a functional phosphatase activity. Proc Natl Acad Sci USA 94: 12479–12484, 1997
Tamura M, Gu J, Matsumoto K, Aota S, Parsons R, Yamada KM: Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN. Science 280: 1614–1617, 1998
Tamura M, Gu J, Takino T, Yamada KM: Tumor suppressor PTEN inhibition of cell invasion, migration, and growth: differential involvement of focal adhesion kinase and p130Cas. Cancer Res 59: 442–449, 1999
Gu J, Masahito T, Yamada KM: Tumor suppressor PTEN inhibits integrin and growth factor mediated mitogen activated protein (MAP) kinase signaling pathways. J Cell Biol 143: 1375–1383, 1998
Gu J, Tamura M, Pankov R, Danen EH, Takino T, Matsumoto K, Yamada KM: Shc and FAK differentially regulate cell motility and directionality modulated by PTEN. J Cell Biol 146: 389–403, 1999
Davies MA, Lu Y, Sano T, Fang X, Tang P, LaPushin R, Koul D, Bookstein R, Stokoe D, Yung WKA, Mills GB, Steck PA: Adenoviral transgene expression of MMAC/PTEN in human glioma cells inhibits Akt activation and induces anoikis. Cancer Res 58: 5285–5290, 1998
Rodrigues GA, Falasca M, Zhang Z, Ong SH, Schlessinger J: A novel positive feedback loop mediated by the docking protein Gab1 and phosphatidylinositol 3-kinase in epidermal growth factor receptor signaling. Mol Cell Biol 20: 1448–1459, 2000
Li DM, Sun H: PTEN/MMAC1/TEP1 suppresses the tumorigenicity and induces G1 cell cycle arrest in human glioblastoma cells. Proc Natl Acad Sci USA 95: 15406–15411, 1998
Furnari FB, Huang HJS, Cavenee WK: The phosphoinositol phosphatase activity of PTEN mediates a serum sensitive G1 growth arrest in glioma cells. Cancer Res 58: 5002–5008, 1998
Delcommenne M, Tan C, Gray V, Rue L, Woodgett J, Dedhar S: Phosphoinositide-3-OH kinase-dependent regulation of glycogen synthase kinase 3 and protein kinase B/Akt by the integrin linked kinase. Proc Natl Acad Sci USA 95: 11211–11216, 1998
Haas-Kogan D, Shalev N, Wong M, Mills G, Yount G, Stokoe D: Protein kinase B (PKB/Akt) activity is elevated in glioblastoma cells due to mutation of the tumor suppressor PTEN/MMAC. Curr Biol 8: 1195–1198, 1998
Morimoto AM, Tomlinson MG, Nakatani K, Bolen JB, Roth RA, Herbst R: The MMAC1 tumor suppressor phosphatase inhibits phospholipase C and integrin linked kinase activity. Oncogene 19: 200–209, 2000
Paramio JM, Navarro M, Segrelles C, Gomez-Casero E, Jorcano JL: PTEN tumor suppressor is linked to the cell cycle control through the retinoblastoma protein. Oncogene 18: 7462–7468, 1999
Westwick JK, Lambert QT, Clark GJ, Symons M, Van AL, Pestell RG, Der CJ: Rac regulation of transformation, gene expression, and actin organization by multiple, PAK-independent pathways. Mol Cell Biol 17: 1324–1335, 1997
Gille H, Downward J: Multiple Ras effector pathways contribute to G1 cell cycle. J Biol Chem 274: 22033–22040, 1999
Gjoerup O, Lukas J, Bartek J, Willumsen BM: Rac and Cdc42 are potent stimulators of E2F-dependent transcription capable of promoting retinoblastoma susceptibility gene product hyperphosphorylation. J Biol Chem 273: 18812–18818, 1997
Diehl JA, Cheng M, Roussel MF, Sherr CJ: Glycogen synthase kinase 3 β regulates cyclin D1 proteolysis and subcellular localization. Genes Dev 12: 3499–3511, 1998
Muise-Helmericks RC, Grimes HL, Bellacosa A, Malstrom SE, Tsichlis PN, Rosen N: Cyclin D expression is controlled post-transcriptionally via a phosphatidylinositol 3-Kinase/Akt-dependent pathway. J Biol Chem 273: 29864–29872, 1998
Marshall C: How do small GTPase signal transduction pathways regulate cell cycle entry. Curr Op Cell Biol 11: 732–736, 1999
Khosravi-Far R, Campbell S, Rossman KL, Der CJ: Increasing complexity of Ras signal transduction: involvement of Rho family proteins. Adv Cancer Res 72: 57–107, 1998
Minden A, Lin A, McMahon M, Lange-Carter C, Derijard B, Davis RJ, Johnson GL, Karin M: Differential activation of ERK and JNK mitogen activated protein kinases by Raf-1 and MEKK. Science 266: 1719–1723, 1994
Feldkamp MM, Lala P, Lau N, Roncarci L, Guha A: Expression of activated epidermal growth factor receptors, ras-guanosine triphosphate, and mitogen activated protein kinase in human glioblastoma multiforme specimens. Neurosurgery 45: 1442–1453, 1999
Guha A, Feldkamp MM, Lau N, Boss G, Pawson A: Proliferation of human malignant astrocytomas is dependent on ras activation. Oncogene 15: 2755–2765, 1997
Feldkamp MM, Lau N, Guha A: Growth inhibition of astrocytoma cells by farnesyl transferase inhibitors is mediated by a combination of anti-proliferative, pro-apoptotic and anti-angiogenic effects. Oncogene 18: 7514–7526, 1999
Zujewski J, Horak ID, Bol CJ, Woestenborghs R, Bowden C, End DW, Piotrovsky VK, Chiao J, Belly RT, Todd A, Kopp WC, Kohler DR, Chow C, Noone M, Hakim FT, Larkin G, Gress RE, Nussenblatt RB, Kremer AB, Cowan KH: Phase I and Pharmacokinetic Study of Farnesyl Protein Transferase Inhibitor R115777 in Advanced Cancer. J Clin Oncol 18: 927, 2000
Barrington RE, Subler MA, Rands E, Omer CA, Miller PJ, Hundley JE, Koester SK, Troyer DA, Bearss DJ, Conner MW, Gibbs JB, Hamilton K, Koblan KS, Mosser SD, O'Neill TJ, Schaber MD, Senderak ET, Windle JJ, Oliff A, Kohl NE: A farnesyltransferase inhibitor induces tumor regression in transgenic mice harboring multiple oncogenic mutations by mediating alterations in both cell cycle control and apoptosis. Mol Cell Biol 18: 85–92, 1998
Lebowitz PF, Davide JP, Prendergast GC: Evidence that farnesyltransferase inhibitors suppress Ras transformation by interfering with Rho activity. Mol Cell Biol 15: 6613–6622, 1995
Coffey MC, Strong JE, Forsyth PA, Lee PWK: Reovirus therapy of tumors with activated ras pathway. Science 282: 1332–1334, 1998
Jaken S. Protein kinase C isozymes and substrates. Curr Op Cell Biol 8: 168–173, 1996
Kolch W, Heldecker G, Kochs G, Hummel R, Vahidi H, Mischak H, Finkenzeller G, Marme D, Rapp UR: Protein kinase Cα activates Raf-1 by direct phosphorylation. Nature 364: 249–252, 1993
Marais R, Light Y, Mason C, Paterson H, Olson MF, Marshall CJ: Requirement of Ras-GTP-Raf complexes for activation of Raf-1 by protein kinase C. Science 280: 109–112, 1998
Bredel M, Pollack IF: The role of protein kinase C (PKC) in the evolution and proliferation of malignant gliomas, and the application of PKC inhibition as a novel approach to anti-glioma therapy. Acta Neurochir 139: 1000–1013, 1997
Baltuch GH, Dooley NP, Villemure JG, Yong VW: Protein kinase C and growth regulation of malignant gliomas. Can J Neurol Sci 22: 264–271, 1995
Lund KA, Lazar CS, Chen WS, Walsh BJ, Welsh JB, Herbst JJ, Walton GM, Rosenfeld MG, Gill GN, Wiley HS: Phosphorylation of the epidermal growth factor receptor at threonine 654 inhibits ligand-induced internalization and down-regulation. J Biol Chem 265: 20517–20523, 1990
Jimenez-deAsua L, Goin M: Prostaglandin F2 alpha decreases the affinity of epidermal growth factor receptors in Swiss mouse 3T3 cells via protein kinase C activation. FEBS Lett 299: 235–238, 1992
Morrison P, Saltiel AR, Rich Rosner M: Role of mitogenactivated protein kinase in regulation of the epidermal growth factor receptor by protein kinase C. J Biol Chem 271: 12891–12896, 1996
Gulliford T, Ouyang X, Epstein RJ: Intensification of growth factor receptor signaling by phorbol treatment of ligand-primed cells implies a dimer-stabilizing effect of protein kinase C-dependent juxtamembrane domain phosphorylation. Cell Signal 11: 245–252, 1999
Mishra-Press A, Fields AP, Samols D, Goldthwait DA: Protein kinase C isoforms in glioblastoma cells. Glia 6: 188–197, 1992
Xiao H, Goldthwait DA, Mapstone T: The identification of four protein kinase C isoforms in human glioblastoma cell lines: PKC alpha, gamma, epsilon, and zeta. J Neurosurg 81: 734–740, 1994
Couldwell WT, Uhm JH, Antel JP, Yong VW: Enhanced protein kinase C activity correlates with the growth rate of malignant gliomas in vitro. Neurosurgery 29: 880–887, 1991
Couldwell WT, Antel JP, Yong VW: Protein kinase C activity correlates with the growth rate of malignant gliomas: part II. Effects of glioma mitogens and modulators of protein kinase C. Neurosurgery 31: 717–724, 1992
Baltuch GH, Yong VW: Signal transduction for proliferation of glioma cells in vitro occurs predominantly through a protein kinase C-mediated pathway. Brain Res 710: 143–149, 1996
Begemann M, Kashimawo SA, Choi YJA, Kim S, Christiansen KM, Duigou G, Mueller M, Schieren I, Ghosh S, Fabbro D, Lampen NM, Heitjan DF, Schiff PB, Bruce JN, Weinstein IB: Inhibition of the growth of glioblastomas by CGP41251, an inhibitor of protein kinase C, and by a phorbol ester tumor promoter. Clin Cancer Res 2: 1017–1030, 1996
Begemann M, Kashimawo SA, Heitjan DF, Schiff PB, Bruce JN, Weinstein IB: Treatment of human glioblastoma cells with the staurosporine derivative CGP 41251 inhibits CDC2 and CDK2 kinase activity and increases radiation sensitivity. Anticancer Res 18: 2275–2282, 1998
Begemann M, Kashimawo SA, Lunn RM, Delohery T, Choi YJA, Kim S, Heitjan DF, Santella RM, Schiff PB, Bruce JN, Weinstein IB: Growth inhibition induced by Ro 31–8220 and calphostin C in human glioblastoma cell lines is associated with apoptosis and inhibition of CDC2 kinase. Anticancer Res 18: 3139–3152, 1998
Ahmad S, Mineta T, Martuza RL, Glazer RI: Antisense expression of protein kinase C alpha inhibits the growth and tumorigenicity of human glioblastoma cells. Neurosurgery 35: 904–909, 1994
Yazaki T, Ahmad S, Chahlavi A, Zylber-Katz E, Dean NM, Rabkin SD, Martuza RL, Glazer RI: Treatment of glioblastoma U87 by systemic administration of an antisense protein kinase C alpha phosphorothioate oligonucleotide. Mol Pharmacol 50: 236–242, 1996
Sioud M, Sorensen DR: Anuclease-resistant protein kinase C α ribozyme blocks glioma cell growth. Nature Biotech 16: 556–561, 1998
Leirdal M, Sioud M: Ribozyme inhibition of the protein kinase C α triggers apoptosis in glioma cells. Br J Cancer 80: 1558–1564, 1999
Shih SC, Mullen A, Abrams K, Mukhopadhyay D, Claffey KP: Role of protein kinase C isoforms in phorbol ester-induced vascular endothelial growth factor expression in human glioblastoma cells. J Biol Chem 274: 15407–15414, 1999
Wellner M, Maasch C, Kupprion C, Lindschau C, Luft FC, Haller H: The proliferative effect of vascular endothelial growth factor requires protein kinase C-α and protein kinase C-ζ. Arterioscler Thromb Vasc Biol 19: 178–185, 1999
Besson A, Yong VW: Involvement of p21/Waf1/Cip1 in protein kinase C alpha-induced cell cycle progression. Mol Cell Biol 20: 4580–4590, 2000
LaBaer J, Garrett MD, Stevenson LF, Slingerland JM, Sandhu C, Chou HS, Fattaey A, Harlow E: New functional activities for the p21 family of CDK inhibitors. Genes Dev 11: 847–862, 1997
Cheng M, Olivier P, Diehl JA, Fero M, Roussel MF, Roberts JM, Sherr CJ: The p21(Cip1) and p27(Kip1) CDK ‘inhibitors’ are essential activators of cyclin D-dependent kinases in murine fibroblasts. EMBO J 18: 1571–1583, 1999
Jung JM, Bruner JM, Ruan S, Langford LA, Kyristis AP, Kobayashi T, Levin VA, Zhang W: Increased levels of p21/Waf1/Cip1 in human brain tumors. Oncogene 11: 2021–2028, 1995
Korkolopoulou P, Kouzelis K, Christodoulou P, Papanikolaou A, Thomas-Tsagli E: Expression of retinoblastoma gene product and p21/Waf1/Cip1 protein in gliomas: correlation with proliferation markers, p53 expression and survival. Acta Neuropathol 95: 617–624, 1998
Couldwell WT, Hinton DR, Surnock AA, DeGiorgio CM, Weiner LP, Apuzzo MLJ, Masri L, Law RE, Weiss MH: Treatment of recurrent malignant gliomas with chronic oral high-dose tamoxifen. Clin Cancer Res 2: 619–622, 1996
Mastronardi L, Puzzilli F, Couldwell WT, Osman Farah J, Lunardi P: Tamoxifen and carboplatin combinational treatment of high-grade gliomas. J Neuro-Oncol 38: 59–68
Grossman SA, Alavi K, Carson K, Priet R, Dorr A, Holmlund J: The efficacy of an antisense oligonucleotide directed against protein kinase C alpha (ISIS 3521) delivered as a 21-day continuous intravenous infusion in patients with recurrent high-grade astrocytomas. Abstract #84 for the Society of Neuro-oncology 1999. Neuro-Oncology 1: 313, 1999
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Besson, A., Wee Yong, V. Mitogenic Signaling and the Relationship to Cell Cycle Regulation in Astrocytomas. J Neurooncol 51, 245–264 (2001). https://doi.org/10.1023/A:1010657030494
Issue Date:
DOI: https://doi.org/10.1023/A:1010657030494